Literature DB >> 16129733

Evidence for a secondary state of the human beta3-adrenoceptor.

Jillian G Baker1.   

Abstract

There are three members of the beta-adrenoceptor family, all of which are primarily coupled to G(s) proteins. Recent studies using the huge range of beta-ligands now available have given remarkable new insights into their pharmacology. beta1-adrenoceptors exist in at least two active conformations, whereas beta2-adrenoceptors are able to induce signaling via different agonist-induced receptor conformational states, and their affinity for antagonists can be altered by highly efficacious agonists. This study therefore examined the pharmacology of the human beta3-adrenoceptor stably expressed in Chinese hamster ovary cells. Several compounds described previously as beta-antagonists have agonist properties at the beta3-adrenoceptor. Antagonist affinity measurements varied at the beta3-adrenoceptor in a manner similar to those observed at human beta1-adrenoceptors and unlike those seen at beta2-adrenoceptors. Some ligands (e.g., fenoterol and cimaterol) were more readily inhibited by all antagonists, whereas other ligands [e.g., alprenolol and 1-(2-ethylphenoxy)-3-[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]-(2S)-2-propanol hydrochloride [SR 59230A]) stimulated responses that were more resistant to antagonism. Alprenolol inhibited fenoterol-induced beta3-adrenoceptor responses while acting as an agonist at higher concentrations. This is highly suggestive of two active conformational states of the beta3-adrenoceptor. (S)-4-[2-Hydroxy-3-phenoxypropylaminoethoxy]-N-(2-methoxyethyl)phenoxyacetamide (ZD 7114) stimulated a two-component response, of which the first component was more readily antagonized than the second. Taken together, these experiments suggest that the human beta3-adrenoceptor exists in at least two different agonist conformations with a similar high- and low-affinity pharmacology analogous to, if not as pronounced as, the beta1-adrenoceptor. Both conformations are present in living cells and can be distinguished by their pharmacological characteristics. In this respect, the human beta3-adrenoceptor seems similar to the human beta1-adrenoceptor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16129733     DOI: 10.1124/mol.105.015461

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  15 in total

1.  What systems can and can't do.

Authors:  T Kenakin
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

2.  β(3) Receptors: Role in Cardiometabolic Disorders.

Authors:  Shraddha V Bhadada; Bhoomika M Patel; Anita A Mehta; Ramesh K Goyal
Journal:  Ther Adv Endocrinol Metab       Date:  2011-04       Impact factor: 3.565

3.  The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.

Authors:  Jillian G Baker
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

4.  Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor.

Authors:  Jillian G Baker; Richard G W Proudman; Stephen J Hill
Journal:  Mol Pharmacol       Date:  2014-03-07       Impact factor: 4.436

5.  Beta3 adrenoceptors substitute the role of M(2) muscarinic receptor in coping with cold stress in the heart: evidence from M(2)KO mice.

Authors:  Jan Benes; Martina Novakova; Jana Rotkova; Vladimir Farar; Richard Kvetnansky; Vladimir Riljak; Jaromir Myslivecek
Journal:  Cell Mol Neurobiol       Date:  2012-01-06       Impact factor: 5.046

6.  A study of antagonist affinities for the human histamine H2 receptor.

Authors:  J G Baker
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

7.  A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors.

Authors:  Jillian G Baker
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

Review 8.  The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists.

Authors:  Jonathan R S Arch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-09       Impact factor: 3.000

9.  Metabolic responses to BRL37344 and clenbuterol in soleus muscle and C2C12 cells via different atypical pharmacologies and beta2-adrenoceptor mechanisms.

Authors:  R A Ngala; J O'Dowd; S J Wang; A Agarwal; C Stocker; M A Cawthorne; J R S Arch
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

10.  Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists.

Authors:  Shailesh N Mistry; Jillian G Baker; Peter M Fischer; Stephen J Hill; Sheila M Gardiner; Barrie Kellam
Journal:  J Med Chem       Date:  2013-05-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.